Future Studies to Improve Cryocompression Application in Gynecologic Cancer

Video

Future research assessing cryocompression for those with gynecologic cancers will make use of different products to make the intervention easier and more accessible for patients.

At The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, Mary Katherine Montes de Oca, MD, spoke about plans to further investigate the use of cryocompression to reduce chemotherapy-induced peripheral neuropathy in patients with gynecologic cancers.

According to Montes de Oca, an Obstetrics and Gynecology resident at Duke University Medical Center, a limitation of the self-controlled trial involved application of cryocompression to 1 side of a patient’s body; a future randomized trial may change this by having patients receive the intervention on the entirety of their body. Additionally, she described the possibility of using other methods to allow patients to slide on shoes, gloves, or socks more easily for cryocompression, making the strategy more accessible.

Transcript:

We have a few ideas for a future study. I did a self-controlled design, which means the patient received ice and compression on one side and then had no intervention on the opposite side. If it works, then that means that patients have neuropathy on 1 side of their body. So, plans for future studies would be conventional randomization so that patients can receive the intervention on all of their limbs.

[We] also want to look into some better methods of applying the cryocompression. We used a compression sock, a tight surgical glove, and then bags of ice on the hands and feet. But there are some products that are made by different companies that are just a better method for sliding on the gloves, shoes, or socks, and are a little easier to use and also can be accessible to all of our patients.

Reference

Montes de Oca MK, Unnithan S, Erkanli AE, et al. Use of cryocompression to reduce peripheral neuropathy in gynecologic cancer: a randomized controlled trial. Presented at: 2023 SGO Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, Florida.

Recent Videos
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Related Content